

Please try another search
Wednesday, January 19, 2022The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Roche...
Denmark-based biotech Genmab (NASDAQ:GMAB) A/S GMAB announced that it has initiated a phase III study evaluating the investigational antibody-drug conjugate tisotumab vedotin as compared to...
Roche RHHBY (OTC:RHHBY) announced that the FDA has approved the label expansion of asthma drug, Xolair. The agency approved the company’s supplemental Biologics License Application (sBLA) for...
Blueprint Medicines (NASDAQ:BPMC) Corporation BPMC announced that the European Commission (EC) has granted conditional marketing authorization to its lead drug Ayvakyt (avapritinib) as a monotherapy...
Blueprint Medicines Corporation (NASDAQ:BPMC) incurred a loss of $1.35 per share in the fourth quarter of 2019, narrower than the Zacks Consensus Estimate of a loss of $1.71 and also the year-ago...
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) announced that the FDA has accepted the new drug application (NDA) for its investigational pipeline candidate ripretinib. The company is seeking...
Blueprint Medicines Corporation (NASDAQ:BPMC) announced that the FDA has extended the review period of a new drug application (“NDA”) for its lead pipeline candidate, avapritinib, by...
Eli Lilly and Company (NYSE:LLY) announced that the FDA has granted priority review to its new drug application (NDA) for selpercatinib (LOXO-292), an oral RET inhibitor. The NDA is seeking approval...
Blueprint Medicines Corporation (NASDAQ:BPMC) announced that it has received the FDA approval for Ayvakit (avapritinib) as a treatment of unresectable or metastatic gastrointestinal stromal tumor...
Blueprint Medicines Corporation (NASDAQ:BPMC) announced top-line data from a phase I/II study on its investigational precision therapy pralsetinib, which is being developed for addressing...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review